GeoVax Receives Notice of Allowance for HIV Vaccine Patent
05 oct. 2023 09h00 HE
|
GeoVax, Inc.
ATLANTA, GA, Oct. 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
GeoVax to Participate in Upcoming October Investor and Industry Events
27 sept. 2023 09h00 HE
|
GeoVax, Inc.
Company to Provide Updates on Phase 2 Clinical Trialsfor Next Generation COVID-19 Vaccine and Cancer Immunotherapy Programs ATLANTA, GA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- via...
GeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine Development
26 sept. 2023 09h00 HE
|
GeoVax, Inc.
ATLANTA, GA and BERLIN, Germany, Sept. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against...
GeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia Conference
20 sept. 2023 09h00 HE
|
GeoVax, Inc.
Preclinical Data for GEO-CM02 Demonstrates Single-Dose ProtectionAgainst Multiple SARS-CoV-2 Variants ATLANTA, GA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq:...
GeoVax Next-Generation COVID-19 Vaccine Demonstrates Potent Antibody and Cellular Immunity in Immunocompromised Patients
19 sept. 2023 09h00 HE
|
GeoVax, Inc.
Data Published From Phase 2 Open-Label Study of GEO-CM04S1 ATLANTA, GA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing...
GeoVax Presents Corporate Update at the H.C. Wainwright 25th Annual Global Investment Conference
12 sept. 2023 09h00 HE
|
GeoVax, Inc.
Updates Presented for Gedeptin® and GEO-CM04S1 Phase 2 Clinical Trials ATLANTA, GA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a...
GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster
11 sept. 2023 09h00 HE
|
GeoVax, Inc.
Multi-antigen Vaccine Designed to Protect Against Evolving SARS-CoV-2 Variants ATLANTA, GA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...
GeoVax to Present at the H.C. Wainwright 25th Annual Global Investment Conference
31 août 2023 09h00 HE
|
GeoVax, Inc.
Company to Provide Updates on Multiple Phase 2 Clinical Trials for GEO-CM04S1 and Gedeptin® ATLANTA, GA, Aug. 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc....
GeoVax to Present at the Emerging Growth Conference on September 6, 2023
29 août 2023 09h00 HE
|
GeoVax, Inc.
Company to Provide Updates on Multiple Phase 2 Clinical Trials for its Next-Generation COVID-19 Vaccine and Cancer Immunotherapy Programs ATLANTA, GA, Aug. 29, 2023 (GLOBE NEWSWIRE) --...
GeoVax Receives Notice of Allowance for Malaria Vaccine Patent
28 août 2023 09h00 HE
|
GeoVax, Inc.
Patent Covers Multiple Component Vaccine for Both Prevention and Treatment ATLANTA, GA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a...